The redesign of the Medicare Part D benefit aims to cap out-of-pocket spending but simultaneously shifts significant financial liabilities onto private payers. This regulatory pivot represents one of the most substantial transformations in the pharmaceutical landscape since the inception of the
Internal friction is mounting within the White House as President Trump reportedly grows impatient with the pace of the research mission led by Secretary Kennedy and his circle of political appointees. This frustration stems from a fundamental shift in the federal approach to childhood
A growing number of healthcare stakeholders are voicing concerns that the proprietary nature of the CPT system creates an opaque environment that hides the true cost of medical care. This system, known as the Current Procedural Terminology, is maintained by the American Medical Association, a
Capital is currently concentrating on high-cost chronic conditions, with cardiovascular disease and nephrology startups securing hundreds of millions in funding as healthcare systems seek to reduce long-term management expenses. This strategic pivot reflects a broader shift within the European
Citius Pharmaceuticals is leveraging a staggering 86 percent overall response rate from Phase 1 trials of LYMPHIR as a pretreatment for CAR-T therapy in large B-cell lymphoma. This clinical success arrives at a pivotal moment as the company navigates the complex transition from a research-oriented
Medical device seizures and withdrawals are often caused by preventable labeling errors, making senior-level regulatory judgment an essential part of the compliance process. The transition from the old regulatory framework to the current European Union Medical Device Regulation (EU MDR) has
